Home ›
Entities
› academia
› Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Research article (Cancer Discovery, 2023) · cited 89× · AI/ML
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Summary
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia is a scholarly article[1].
Key Facts
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia's instance of is recorded as scholarly article[2].
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Retrieved May 24, 2026, from https://4ort.xyz/entity/discovery-and-clinical-proof-of-concept-of-rly-2608-a-first-in-class-mutant-selective-allosteric-pi3k-inhibitor-that-dec
MLA“Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/discovery-and-clinical-proof-of-concept-of-rly-2608-a-first-in-class-mutant-selective-allosteric-pi3k-inhibitor-that-dec.
BibTeX@misc{4ortxyz_discovery-and-clinical-proof-of-concept-of-rly-2608-a-first-in-class-mutant-selective-allosteric-pi3k-inhibitor-that-dec_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia}}, year = {2026}, url = {https://4ort.xyz/entity/discovery-and-clinical-proof-of-concept-of-rly-2608-a-first-in-class-mutant-selective-allosteric-pi3k-inhibitor-that-dec}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia — https://4ort.xyz/entity/discovery-and-clinical-proof-of-concept-of-rly-2608-a-first-in-class-mutant-selective-allosteric-pi3k-inhibitor-that-dec (retrieved 2026-05-24)
